Sinaptica Therapeutics
Medical Devices, 330 Brookline Ave, Cambridge, Massachusetts, 02215, United States, 1-10 Employees
Phone Number: +16*********
Who is SINAPTICA THERAPEUTICS
Sinaptica TherapeuticsTM is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimers Disease (AD). The company was...
Read More
-
Headquarters: 330 Brookline Ave, Cambridge, Massachusetts, 02215, United States
-
Employees: 1-10
-
Revenue: $1 Billion and Over
Industry: Medical Devices
SIC Code: 8011
|
NAICS Code: 621111 |
Show More
Does something look wrong? Fix it. | View contact records from SINAPTICA THERAPEUTICS
Sinaptica Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Sinaptica Therapeutics
Answer: Sinaptica Therapeutics's headquarters are located at 330 Brookline Ave, Cambridge, Massachusetts, 02215, United States
Answer: Sinaptica Therapeutics's phone number is +16*********
Answer: Sinaptica Therapeutics's official website is https://sinapticatx.com
Answer: Sinaptica Therapeutics's revenue is $1 Billion and Over
Answer: Sinaptica Therapeutics's SIC: 8011
Answer: Sinaptica Therapeutics's NAICS: 621111
Answer: Sinaptica Therapeutics has 1-10 employees
Answer: Sinaptica Therapeutics is in Medical Devices
Answer: Sinaptica Therapeutics contact info: Phone number: +16********* Website: https://sinapticatx.com
Answer: Sinaptica TherapeuticsTM is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimers Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The companys SinaptiStimTM System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the company's neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimers patients in over two decades, and is protected by multiple pending patents.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month